Level-1 Data From the REDUCE Study and the PCPT Data

October 2015 in “ Prostate Cancer ”

Goutham Vemana, Gerald L. Andriole

5-alpha-reductase inhibitors finasteride dutasteride prostate cancer PSA Propecia Avodart

From the encyclopedia

Frontline, gold standard treatment for combatting androgenic alopecia

Heavy duty finasteride that comes with higher risks

Studysummary This study found that both finasteride and dutasteride reduced the risk of prostate cancer detection, but finasteride was associated with an increased diagnosis of higher-grade disease, unlike dutasteride.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

The document discussed two major studies evaluating the impact of 5-alpha-reductase inhibitors on prostate cancer risk. The Prostate Cancer Prevention Trial focused on men with low baseline PSA levels and found that finasteride significantly reduced the risk of prostate cancer detection, although it was associated with an increased diagnosis of higher-grade disease. The REDUCE trial examined the effects of dutasteride in men with elevated PSA levels, showing a significant reduction in prostate cancer risk without a statistical increase in higher-risk disease compared to placebo.

View this study on sciencedirect.com →

Discuss this study in the Community →

Research cited in this study

5 / 5 results

research Marked Suppression of Dihydrotestosterone in Men with Benign Prostatic Hyperplasia by Dutasteride, a Dual 5α-Reductase Inhibitor

408 citations , May 2004 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism”

This study found that dutasteride more effectively reduced serum dihydrotestosterone levels than finasteride in patients with benign prostatic hyperplasia.

research 5alpha-Reductase: History and Clinical Importance

62 citations , January 2004 in “PubMed”

This review describes the shift in treating symptomatic benign prostatic hyperplasia from surgery to 5alpha-reductase inhibitor drugs, which may provide symptom relief and alter BPH's progression, but reports no new clinical results.

research The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia

1707 citations , December 2003 in “The New England Journal of Medicine”

Combination therapy of doxazosin and finasteride safely and effectively reduces benign prostatic hyperplasia progression risk.

research 5α-Reductase Activity in the Prostate

237 citations , December 2001 in “Urology”

This review discusses the role of 5α-reductase in prostate development and BPH, and reports no new clinical results; ongoing trials are exploring dual isozyme inhibitors for improved treatment efficacy.

The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment Among Men with Benign Prostatic Hyperplasia

research The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment Among Men with Benign Prostatic Hyperplasia

1054 citations , February 1998 in “The New England Journal of Medicine”

In this study, men with benign prostatic hyperplasia who took finasteride for four years experienced reduced urinary symptoms, fewer surgeries, less acute urinary retention, increased urinary flow rates, and decreased prostate volume.